Vaccine adjuvants have moved from a peripheral formulation concern to a central element of modern immunization strategy. As vaccine developers shift toward recombinant proteins, mRNA platforms, and therapeutic applications, antigens alone frequently fail to generate durable, protective immune responses. Adjuvants bridge that gap — amplifying, directing, and extending immunity in ways that determine whether a vaccine reaches clinical utility. Their role in pandemic preparedness, cancer immunotherapy, and routine immunization programs has placed them squarely in the spotlight of pharmaceutical investment.
The Global Vaccine Adjuvants Market was valued at $2.3 billion in 2025 and is projected to reach $3.1 billion by 2031, growing at a CAGR of 5.5% over the 2026–2031 forecast period. That steady expansion reflects both the maturity of established adjuvant platforms and the momentum building behind next-generation technologies. Saponin-based adjuvants and emulsion systems are growing fastest among product types, while the cancer disease segment is the single fastest-growing application, projected at a 7.8% CAGR through 2031.
The companies shaping this market span large integrated pharmaceutical groups, specialist lipid and botanical extract suppliers, and research-tool providers. Together they define the supply chain that runs from raw adjuvant inputs through GMP-scale manufacturing to licensed vaccine formulations. Below is a look at the ten key players and what each brings to this evolving space.
Among adjuvant types, particulate-based adjuvants remain the largest segment at $731.4 million in 2025, anchored by aluminum-based systems with decades of safety data in hepatitis, diphtheria, tetanus, and pertussis vaccines. Emulsion adjuvants, at $598.7 million, are growing at 7.1% CAGR — the fastest of any adjuvant type — driven by MF59-based influenza vaccines and pandemic preparedness stockpiling. Saponin-based adjuvants at $452.3 million follow closely at 6.4% CAGR, fueled by QS-21 and Matrix-M demand in cancer immunotherapy and recombinant vaccine candidates. By application end-user, human vaccines dominate at $2.1 billion, with prophylactic vaccines accounting for the largest sub-segment, while research applications are growing at 7.0% CAGR as biotechnology and academic investment in next-generation vaccine platforms accelerates.
North America holds the largest regional share at 42.1%, backed by strong government funding mechanisms such as BARDA, advanced biopharmaceutical infrastructure, and early adoption of novel adjuvant technologies. Europe accounts for 27.3% of the market, with GSK, Croda International, SEPPIC, and Sanofi collectively anchoring regional innovation. Asia-Pacific is the fastest-growing region at 6.5% CAGR, led by China within the region, as rising immunization coverage and expanding local manufacturing capacity draw increased investment. South America accounts for 4.8% of the market, underpinned by Brazil's National Immunization Program and domestic manufacturers. The Middle East and Africa region is growing at 6.0% CAGR overall, with the Middle East sub-region registering the highest sub-regional CAGR of 6.2%.
• Headquarters: East Yorkshire, U.K.
• Founded: 1925
• Revenue: $2,240.6 million (FY2025)
• Employees: 5,954
• Focus: Pharmaceutical-grade lipids, lipid nanoparticle platforms, liposomal adjuvant systems, mRNA and recombinant vaccine delivery
Croda occupies a strategically important position in the adjuvant supply chain through its life sciences and pharmaceutical ingredients divisions. The company is developing sustainable squalene via biotechnology and fermentation as a replacement for traditionally sourced emulsion inputs, and has partnered with Botanical Solutions Inc. to produce pharmaceutical-grade QS-21 through plant tissue culture. A collaboration with the Access to Advanced Health Institute supports adjuvant innovation and access. Croda's Avanti Research subsidiary extends its reach into LNP-based delivery for mRNA vaccines.
• Headquarters: Melbourne, Victoria, Australia
• Founded: 1916
• Revenue: $15,558 million (FY2024)
• Employees: 29,000
• Focus: Plasma-derived therapies, recombinant products, adjuvanted influenza vaccines, MF59 adjuvant technology
CSL's vaccine business, operating through CSL Seqirus, is one of the primary commercial deployers of adjuvant technology in licensed vaccines. Its proprietary MF59 emulsion adjuvant is formulated into Fluad, a seasonal influenza vaccine targeting older adults with reduced immunogenicity. In 2024, CSL secured a $121.4 million BARDA award to expand MF59 stockpiles to approximately 40 million doses, and a separate $34 million agreement to supply MF59-adjuvanted H5N1 vaccines for pre-pandemic preparedness. Its integrated research, manufacturing, and distribution capabilities support both commercial and emergency-use applications.
• Headquarters: London, U.K.
• Founded: 2000
• Revenue: $43,069.4 million (FY2025)
• Employees: 66,841
• Focus: Vaccines, specialty medicines, oncology, HIV, respiratory, immunology and inflammation
GSK is the market's most visible deployer of proprietary adjuvant systems, with its AS01 platform underpinning two major licensed products. Shingrix, adjuvanted with AS01B, has received expanded regulatory clearance in China for high-risk adults aged 18 and older. Arexvy, adjuvanted with AS01E, has received U.S. label expansion to adults aged 50 to 59 at higher risk and European Commission approval for adults 18 and older. GSK maintains a pipeline of approximately 58 medicines and vaccines, with oncology and next-generation infectious disease vaccines among its strategic priorities, operating across approximately 75 countries.
• Headquarters: Gaithersburg, Maryland, U.S.
• Founded: 1987
• Revenue: $1,123.5 million (FY2025)
• Employees: 749
• Focus: Recombinant protein nanoparticle vaccines, Matrix-M adjuvant, licensing and royalties
Novavax has repositioned its Matrix-M adjuvant as a platform asset with growing licensing value beyond its own product portfolio. In 2025, it updated its Sanofi collaboration to include pandemic influenza vaccine development using Matrix-M. In 2026, it signed a non-exclusive license with Pfizer covering Matrix-M use across up to two disease areas. The 2025–2026 formulation of its Nuvaxovid COVID-19 vaccine received U.S. approval. Adjuvant research and manufacturing are conducted at its Uppsala, Sweden facility, supporting both internal pipeline advancement and external partnerships.
• Founded: 1996
• Employees: 405
• Focus: CpG-based adjuvant technologies, TLR agonist platforms, vaccines, biopharmaceutical development
Dynavax built its commercial position around CpG 1018, a TLR9-activating oligonucleotide adjuvant used in HEPLISAV-B, its two-dose hepatitis B vaccine. In 2023, HEPLISAV-B received marketing authorization in Great Britain, expanding its geographic footprint. Dynavax was acquired by Sanofi on February 10, 2026, and now operates as a fully owned subsidiary. Sanofi has integrated HEPLISAV-B and the Z-1018 shingles vaccine candidate, currently in Phase 1/2 clinical development, into its portfolio, along with the broader CpG 1018 adjuvant platform.
• Headquarters: Alabaster, Alabama, U.S.
• Founded: 1967
• Focus: High-purity lipids, lipid nanoparticle delivery, pharmaceutical and life sciences applications, vaccine adjuvant formulations
Operating as a subsidiary of Croda International, Avanti Research focuses on the supply of well-characterized lipids and lipid-based excipients for drug delivery and vaccine formulation. In 2025, the company expanded its Pennsylvania lipid manufacturing facility with BARDA support, increasing production capacity for components used in mRNA vaccine delivery systems. A collaboration with Certest Biotec supports ionizable lipid access across research through GMP-scale manufacturing. Avanti serves preclinical and early development workflows, providing reference-grade immunostimulatory components to vaccine adjuvant programs.
• Headquarters: Chula Vista, California, U.S.
• Founded: 1978
• Focus: Saponin-based vaccine adjuvants, Quillaja saponaria botanical extracts, animal health, food and beverages, agriculture
Desert King is a primary supplier of Quillaja saponaria extracts, which form the botanical foundation of QS-21-derived adjuvant systems. In 2025, the company opened a new production facility that raised Quillaja extract capacity by approximately 60%. It simultaneously established a forestry division dedicated to sustainable cultivation of Quillaja saponaria, improving long-term supply chain traceability. A 2025 collaboration with the Vaccine Formulation Institute supports expanded access to QS-21-based adjuvant systems for vaccine development and global health initiatives.
• Headquarters: San Diego, California, U.S.
• Founded: 1997
• Focus: Life science research tools, vaccine adjuvant reagents, immunology tools
InvivoGen serves the research and preclinical segment of the adjuvant market, supplying immunostimulatory tools that span particulate adjuvants, emulsion systems, and defined innate immune activators targeting PRR, STING, and TLR pathways. In 2024, it partnered with SaponiQx to commercialize STIMULON cpcQS-21, a cultured plant cell-derived QS-21, broadening researcher access to this adjuvant class. A collaboration with Bioz integrates AI-driven, publication-based product insights into InvivoGen's platform, helping researchers identify and select validated adjuvant reagents for experimental vaccine programs.
• Headquarters: La Garenne-Colombes, France
• Founded: 1943
• Focus: Pharmaceutical ingredients, vaccine adjuvant technologies, cosmetic and nutraceutical ingredients, specialty chemicals
SEPPIC, a subsidiary of Air Liquide, develops emulsion-based and polymeric adjuvant systems with applications in both human and veterinary vaccine programs. In 2025, SEPPIC partnered with the Vaccine Formulation Institute to launch industrial-scale availability of the open-access saponin-based emulsion adjuvant 'SQ', which combines a squalene oil-in-water emulsion with a QS-21-derived component. The company distributes to over 100 countries and maintains manufacturing and research operations in France, Germany, China, and the U.S., positioning it as a broadly accessible adjuvant ingredient supplier for global vaccine developers.
• Headquarters: Wilmington, Delaware, U.S.
• Founded: 1964
• Focus: Pharmaceutical excipients, aluminum-based adjuvants, saponin-based adjuvants, synthetic TLR4 agonists, integrated adjuvant systems
SPI Pharma's adjuvant offering spans traditional alum formulations through to advanced combination platforms. In 2024, the company launched the 'Valens' brand to consolidate its vaccine adjuvant and biologic ingredient portfolio. A partnership with Inimmune Corp. led to the development of Valens T4Q and Valens T4AH, two next-generation TLR4-based adjuvant systems extending beyond conventional aluminum formulations. SPI Pharma operates facilities in the U.S., France, and India, distributes to over 55 countries, and serves customers across North America, Europe, and Asia.
The Global Vaccine Adjuvants Market reflects a technology segment in active transition. Established platforms — aluminum salts, MF59, and CpG-based systems — continue to anchor licensed vaccine programs, while saponin-based, nanoparticle-based, and synthetic TLR agonist systems are generating faster growth and attracting the most strategic investment. The licensing activity around Matrix-M, the BARDA-backed expansion of MF59 stockpiles, and the commercialization of sustainable QS-21 sourcing all signal a market that is simultaneously scaling and diversifying its technological base.
The ten companies profiled here collectively represent the breadth of the adjuvant supply chain — from botanical raw material extraction and lipid manufacturing through GMP-scale adjuvant production to licensed vaccine formulation and research reagent supply. Their strategic moves over 2023–2026 suggest that the next competitive battleground will be defined by platform licensing reach, supply chain resilience for biologically sourced inputs, and the ability to support the emerging therapeutic vaccine segment, where adjuvant performance requirements are substantially more demanding than in conventional prophylactic applications.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.